Berberine Inhibits SASP Inflammation via RXRα/PPARγ

Atherosclerotic plaques contain macrophages and foam cells that can acquire senescence-associated secretory phenotypes (SASP), sustaining cytokine, chemokine, and tissue-remodeling activity. The reference study by Zheng and colleagues, published in 2025, examines how berberine limits this inflammatory state and proposes a receptor-to-protein-degradation mechanism centered on RXRα, PPARγ, and NEDD4.

The study is important because it moves beyond the observation that berberine has anti-inflammatory or anti-senescence activity. It connects those effects to activation of an RXRα/PPARγ signaling module, increased NEDD4 transcription, and ubiquitination-mediated degradation of a GATA4/p62 complex. The findings do not establish a general anti-aging effect in humans, but they provide a testable model for studying nuclear-receptor control of plaque inflammation.

Study Background and Research Question

Cellular senescence is associated with persistent DNA damage responses, mitochondrial dysfunction, and a secretory program that alters the surrounding tissue. SASP factors can include inflammatory cytokines, chemokines, growth factors, and matrix-remodeling proteins. In vascular disease, this chronic signaling may amplify leukocyte recruitment, plaque instability, and local tissue damage.

Macrophage-derived foam cells are especially relevant because macrophages internalize oxidized low-density lipoprotein (ox-LDL) within plaques. Oxidative stress generated in this setting can reinforce both foam-cell formation and senescence-associated inflammation. The reference study also draws on human carotid plaque single-cell sequencing, which has identified abundant inflammatory macrophages and aging foam-cell populations. These observations support the use of macrophage and foam-cell systems to investigate SASP biology rather than treating senescence as an isolated cellular event.

The central research question was whether berberine suppresses atherosclerotic SASP through a defined molecular pathway. More specifically, the investigators asked whether RXRα and its partner PPARγ regulate NEDD4, an E3 ubiquitin ligase, and whether this regulation controls the stability of GATA4/p62 complexes linked to inflammatory protein production.

Key Innovation from the Reference Study

The principal innovation is the proposed RXRα/PPARγ/NEDD4 axis. According to the reference paper, berberine activates RXRα and PPARγ in macrophage-derived foam cells. These receptors act together to increase NEDD4 transcriptional activity. NEDD4 then promotes ubiquitination associated with degradation of the GATA4/p62 complex, reducing production of SASP-related inflammatory proteins.

This model adds several layers to the usual description of berberine as a pleiotropic anti-inflammatory compound. First, it places a nuclear-receptor complex upstream of the response. Second, it identifies transcriptional induction of an ubiquitin ligase as an intermediate regulatory step. Third, it links receptor activity to turnover of a protein complex rather than only to short-term changes in cytokine transcription. In this sense, the work describes both PPARγ/RXRα heterodimer modulation and proteostasis control within foam cells.

The study also includes a causal test. When RXRα was knocked down in plaque macrophages using a lentiviral CD68-directed short-hairpin RNA approach, the anti-senescence and anti-inflammatory effects of berberine were diminished. This result supports the requirement of macrophage RXRα for the reported response, although it does not by itself prove that every action of berberine is mediated exclusively by the RXRα/PPARγ/NEDD4 pathway.

Methods and Experimental Design Insights

The investigators used complementary in vivo, ex vivo, and molecular approaches. In an ApoE-deficient mouse model maintained on a high-fat diet, they evaluated plaque morphology and blood chemistry before and after berberine treatment. This design connects pathway activity with disease-relevant phenotypes rather than relying only on cultured cells.

For cellular analysis, the study used RAW264.7 macrophages and foam cells generated from mouse peritoneal macrophages. These models allowed measurement of SASP-associated proteins under a controlled foam-cell and inflammatory environment. The investigators then applied Smart-seq transcriptomic analysis to identify pathways altered by berberine. Molecular findings were integrated with receptor-related assays, protein measurements, and ubiquitination analyses.

The RXRα loss-of-function experiment was particularly useful because it tested pathway necessity in the macrophage compartment of atherosclerotic plaques. A macrophage-directed knockdown strategy is more informative than a global receptor knockout for this question, since whole-animal deletion could introduce effects from hepatocytes, adipocytes, endothelial cells, or other immune populations.

Protocol Parameters

• In vivo disease model: Use ApoE-deficient mice on a high-fat diet when reproducing the reported atherosclerosis framework; consult the full article for the exact berberine dose, treatment schedule, and endpoint timing.
• Cellular models: RAW264.7 cells and peritoneal macrophage-derived foam cells provide the reported systems for measuring SASP-related proteins and receptor-pathway responses.
• Transcriptomic discovery: Apply Smart-seq analysis to compare berberine-treated and control cellular states, then validate candidate pathway changes with protein and functional assays rather than treating transcript abundance as proof of mechanism.
• Causal perturbation: A macrophage-directed RXRα knockdown, such as the lentiviral CD68-shRNA strategy described in the study, can test whether receptor activity is required for the berberine response.
• Mechanistic validation: Pair measurements of RXRα, PPARγ, NEDD4, GATA4, and p62 with ubiquitination or protein-stability assays to distinguish transcriptional regulation from altered protein degradation.

Core Findings and Why They Matter

Berberine was associated with improved plaque-related phenotypes in the ApoE-deficient mouse model, including changes in plaque morphology and blood chemistry. In macrophage and foam-cell systems, it reduced inflammatory proteins associated with SASP. These observations support the interpretation that berberine acts on both the systemic disease model and the local inflammatory behavior of plaque-associated macrophages.

At the mechanistic level, berberine increased the interaction of GATA4 with p62 and promoted ubiquitination linked to degradation of this complex. The resulting reduction in GATA4/p62 abundance was accompanied by lower SASP-associated protein production. This is meaningful because p62 can function as a signaling and scaffold protein, while GATA4 has been implicated in senescence-associated transcriptional programs. Their regulated turnover offers a potential control point between receptor signaling and inflammatory output.

Transcriptomic data supported activation of RXRα and PPARγ together with increased NEDD4 expression. The proposed sequence is therefore: berberine activates the RXRα/PPARγ receptor complex; receptor signaling increases NEDD4 transcription; NEDD4 promotes ubiquitination of the GATA4/p62 complex; and reduced complex stability limits SASP-related inflammation.

The RXRα knockdown experiment strengthened this interpretation. Suppression of macrophage RXRα weakened berberine-mediated protection against the senescence-associated inflammatory phenotype in plaques. However, the result should be understood as evidence that RXRα is an important upstream requirement, not as proof that PPARγ is the only relevant berberine target. Receptor crosstalk, metabolic effects, and other stress-response pathways may still contribute.

Comparison with Existing Internal Articles

The internal article Berberine Suppresses SASP Inflammation via RXRα/PPARγ/NEDD4 Axis provides a concise pathway-focused companion to the primary research report. Its emphasis on the RXRα/PPARγ/NEDD4 axis is consistent with the reference study, whereas the reference paper supplies the experimental context: ApoE-deficient mice, macrophage-derived foam cells, Smart-seq analysis, and macrophage-specific RXRα knockdown.

For literature review purposes, the internal article is best used as an orientation resource, while the published study should remain the basis for evaluating experimental evidence, model limitations, and causal strength. The two resources therefore serve different functions rather than representing independent confirmations of the findings.

Limitations and Transferability

The study has several limitations that affect interpretation. The in vivo evidence comes from a mouse atherosclerosis model, and the response to berberine may differ in human plaques because of species-specific metabolism, plaque composition, and immune-cell heterogeneity. Human carotid single-cell observations provide biological relevance, but they do not constitute an intervention study or demonstrate that the same pathway is therapeutically active in patients.

Berberine is a multifunctional compound, so RXRα knockdown does not exclude RXRα-independent actions. The reported data also support a pathway association and a requirement for RXRα, but stronger evidence for direct receptor activation would require additional approaches such as receptor-binding studies, promoter-level assays, selective PPARγ perturbation, or rescue experiments with pathway components.

Another consideration is model dependence. RAW264.7 cells and peritoneal macrophages do not fully reproduce the diversity of plaque macrophages, smooth-muscle-cell interactions, endothelial signaling, or the extracellular matrix environment. Follow-up work should compare primary human plaque-derived cells, assess temporal relationships among receptor activation and NEDD4 induction, and determine which SASP factors are most closely linked to changes in plaque stability.

Why this cross-domain matters, maturity, and limitations

PPARγ is studied in several biological settings, including lipid handling, adipocyte differentiation, inflammation, and cell-cycle regulation. Nevertheless, the reference study evaluates berberine in atherosclerosis and macrophage senescence; it does not validate the RXRα/PPARγ/NEDD4 mechanism as a universal explanation for PPARγ-dependent effects in other cell types. Cross-domain use should therefore be treated as a hypothesis-generating extension requiring cell-specific controls, not as direct evidence of therapeutic transfer.

Research Support Resources

Researchers can use T0070907 (SKU A4301) as a mechanistic PPARγ antagonist when testing whether a response depends on PPARγ signaling or on PPARγ/RXRα heterodimer modulation. The product information reports an IC50 of 1 nM and a Ki of 1 nM, as well as covalent binding to Cys313 of human PPARγ2. It may support control experiments involving PPARγ signaling pathway inhibition, adipogenesis inhibition, or context-specific cell cycle G2/M arrest assays. These applications should be interpreted as pathway-dissection experiments; they do not demonstrate that T0070907 reproduces berberine's anti-atherosclerotic effects or establish a clinical intervention.